FIELD OF INVENTION

The present invention relates to a prebiotic a composition comprising a prebiotic and a probiotic, and a method of administering a prebiotic, a composition or a probiotic directly into the intestinal tract of mammal.

The present invention relates to the value of Parry's fenupower as prebiotic.

BACKGROUND OF INVENTION

This invention relates generally to the use of prebiotic and probiotic preparations to improve intestinal health and conditions related to microbial populations in the gastrointestinal tract of host humans and animals, and thereby improve the health and well being of the host.
Prebiotics are non digestible food ingredients which stimulate the growth and activity of beneficial microorganisms in the intestinal tract. Prebiotics mainly consist of oligosaccharides, sugar molecules of three to six chains and soluble fiber.

Probiotic bacteria are normally not found in the human in testinal tract, because these bacteria do not colonize well and are eliminated rather quickly, prebiotic food ingredients encourage probiotic organisms to survive and thrive in the human gut.

It has been proven that the symbiotic relationship between prebiotics and probiotics significantly contributes to humans' health. Prebiotics and probiotics together show boost the immune system, help to improve overall health benefits.

Commonly known and used Probiotics have several disadvantages. Some of the prebiotics known have no selective effect on specific intestinal bacteria. This means that theses prebiotics support the growth of all organisms in the intestinal tract, in differently from their benefit to the human health. Other prebiotics cause flatulences, abdominal pain, eructation, bloating stomach, diarrhoea (due to osmogenic retention of fluid in the intestine) or even allergic reactions. Lactulose has been found to be unpalatable and may cause nausea, vomiting, abdominal cramps and diarrhoea. Also currently no prebiotic products are available in market especially for metabolic disorder.

OBJECTIVE OF INVENTION

Object of invention is to develop a novel prebiotic that will work for metabolic disorder.

It is an object of the present invention to provide new novel Probiotics which overcome the disadvantages of the prebiotics known in the art.

DESCRIPTION OF INVENTION

The present invention relates to the use of parry's fenupower as Prebiotics.
Several publications have shown that fenugreek having huge potential values for human health benefits.

It surprisingly turned out that enriched Galacctomannan specifically stimulates the growth of probiotic microorganisms like Bacillus Subtilis, LPIantarum and B. Lactis.

Parry's fenupower is comprised in a probiotic composition comprising at least one probiotic microroganism, in particular probiotic strain.

It turned out that these probiotic microorganisms are especially suited to be combined with parrys fenupower. In particular these probiotics are able to grow significantly better in the presence of parrys fenupower compared to other non-probiotic microorganisms present in the intestinal tract.

Problem solved in the invention:

a. We found fenupower as a superior prebiotic.

b. Fenupower Gl study shown and proven by experimentally.

c. First time Gl index reducing as well as a superior prebiotic

d. A soluble fibre (galactomannan) gets broke down to SCFA and inducing AMPK activity is described.

e. AMPK and SCFA activity is expected to be higher because Galactomannan is a 1:1 ratio of galactose: mannose units.

f. Fenupower containing a at least 70% of Galactomannan. This fenupower is showing to offer the benefits. Hence will give double benefits (Gl and AMPK, SCFA) it is advantages than single benefitable products in existing market.

Description of invention with relevant data's: Possible combinations:
Parry's Fenupower 400 mg
Probiotic Blend 100 mg (1 billion cfu)
B. Subtilis 0.4 billion cfu
L Plantarum Bg2 0.4 billion cfu
B. Lactis ss-72 0.2 billion cfu
Parry's Fenupower 350 mg
FOS 100 mg
Hemicellulase 5mg
Probiotic Blend 100 mg (1 billion cfu)
B. Subtilis 0.4 billion cfu
L Plantarum Bg2 0.4 billion cfu
B. Lactis ss-72 0.2 billion cfu

Parry's Fenupower 300 mg
Spirulina 150 mg
Probiotic Blend 50 mg (1 billion cfu)
B. Subtilis 0.4 billion cfu
L Plantarum Bg2 0.4 billion cfu
B. Lactis ss-72 0.2 billion cfu

Parry's Fenupower 300 mg
Spirulina 100 mg
FOS 50 mg
Hemicellulase 5mg
Probiotic Blend 50 mg (1 billion cfu)
B. Subtilis 0.4 billion cfu
L Plantarum Bg2 0.4 billion cfu
B. Lactis ss-72 0.2 billion cfu

Partially hydrolysed

Parry's Fenupower 300 mg
Spirulina 50 mg (1 billion cfu)
Probiotic Blend 0.4 billion cfu
B. Subtilis 0.4 billion cfu
L. Plantarum Bg2 0.2 billion cfu
B. Lactis ss-72
Partially hydrolysed

Parry's Fenupower 300 mg
Spirulina 50 mg
FOS 5mg
Hemicellulase 50 mg (1 billion cfu)
Probiotic Blend 0.4 billion cfu
B. Subtilis 0.4 billion cfu
L Plantarum Bg2 0.2 billion cfu
B. Lactis s$-72

Prebiotic effects are usually determined by in vitro studies like growth and sporulation. The growth and sporulation study reports are elaborated below.

The invention discloses a dietary supplement containing fenugreek, probiotic blend, B Subtilis, L Plantarum Bg2 & B Lactis ss-72 in the ratio 400 mg : 50-150 mg (0.6billion cfu - 2.4 billion cfu) : 0.5 Billion : 0.5 Billion : 0.3 Billion wherein fenugreek is characterized with 50 - 80% Galacctomannan.

In another aspect, the invention discloses a dietary supplement as claimed in claim 1 wherein the composition further includes FOS, the said composition comprising of fenugreek, probiotic blend, B Subtilis, L Plantarum Bg2, B Lactis ss-72, Hemi cellulose & FOS in the ratio 400 mg : 50-150 mg (0.6billion cfu - 2.4 billion cfu): 0.5 Billion : 0.5 Billion : 0.3 Billion : 5 mg : 100 mg

In another aspect the invention discloses a dietary supplement as claimed in claim 1 wherein the composition further includes spirulina with the ratio of fenugreek, probiotic blend & spirulina which is 300 mg : 50 mg : 150 mg.

In another aspect, the invention discloses a dietary supplement as claimed in claim 1, 2 & 3 wherein the fenugreek is partially hydrolyzed fenugreek.

In-vitro studies: (Refer Fig.1)
Effect of Parry's Fenubiotic and FOS/ inulin/ lactitol on the growth and sporulation with Probiotics:

Growth and sporulation of Probiotics higher in parry's fenubiotic (Fenupower (50 - 80% Galacctomannan): probiotic blend - B Subtilis, L Plantarum Bg2 & B Lactis ss-72 in the ratio 400 mg : 90-1 OOmg (1 billion cfu) than compared to lactitol (1000 mg) where growth was less and 100 % sporulation was achieved only after 24 h.

The effect of 500 mg fenubiotic and 1000 mg FOS/1000 mg inulin was comparable in case of growth of probiotics up to 40 h. In both the cases sporulation started at 8 h. 100 % sporulation was achieved at 16 h in case of fenubiotic whereas it took 24 h to achieve 100 % sporulation in case of FOS/ inulin.

Though Parry's Fenubiotic showed more / comparable growth than half the concentration of FOS/ inulin/lactitol.

We are used acid stable Probiotics compare with existing Probiotics in market.

The invention has been described with few embodiments and illustrations. However the invention is not restricted to these, as a skilled person will be able to arrive at other variations on the basis of this disclosure, all of which are also within the scope of this invention.

WE CLAIM:

1. A dietary supplement containing fenugreek, probiotic blend, B Subtilis, L Plantarum Bg2 & B Lactis ss-72 in the ratio 400 mg : 50-150 mg (0.6billion cfu - 2.4 billion cfu) : 0.5 Billion : 0.5 Billion : 0.3 Billion wherein fenugreek is characterized with 50 - 80% Galacctomannan.

2. The dietary supplement as claimed in claim 1 wherein the composition further includes FOS, the said composition comprising of fenugreek, probiotic blend, B Subtilis, L Plantarum Bg2, B Lactis ss-72, Hemi cellulose & FOS in the ratio 400 mg : 50-150 mg (0.6billion cfu - 2.4 billion cfu): 0.5 Billion : 0.5 Billion : 0.3 Billion : 5 mg : 100 mg

3. The dietary supplement as claimed in claim 1 wherein the composition further includes spirulina with the ratio of fenugreek, probiotic blend & spirulina which is 300 mg :50mg : 150 mg

4. The dietary supplement as claimed in claim 1, 2 & 3 wherein the fenugreek is partially hydrolyzed fenugreek.